In Vitro Diagnostics Contract Manufacturing Market To Reach $37.45 Billion By 2030

In Vitro Diagnostics Contract Manufacturing Market Growth & Trends

The global in vitro diagnostics contract manufacturing market size is expected to reach USD 37.45 billion by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc.

The market is anticipated to witness lucrative growth potential owing to rising demand for diagnostic devices, an upsurge in point-of-care diagnostics, advancements in molecular testing, and the increasing prevalence of chronic diseases. Moreover, the growing need for cost-effective manufacturing, technological innovation, and stringent regulatory compliance for diagnostics is expected to drive the market revenue stream. Thus, the increasing trend for outsourcing manufacturing services to CMOs and CDMOs to access specialized expertise, streamline production, and accelerate time-to-market among healthcare companies is boosting overall market growth.

The high cost of in-house IVD manufacturing is a significant driver propelling the market growth. The need for high capital investment in infrastructure, specialized equipment, regulatory compliance, and skilled workforce to develop and scale up IVD production will accelerate market growth. These overhead costs strain resources, reducing profitability and flexibility among several small and medium-scale organizations. Thus, by outsourcing manufacturing services to CMOs & CDMOs, companies can lower manufacturing costs and gain access to innovative technologies exclusive of the need for internal capital investment. Moreover, outsourcing allows faster market entry, enhanced scalability, and better resource optimization and offers a competitive edge in the IVD market.

Furthermore, continuous technological advancements are among the major factors accelerating the market demand, specifically for diagnostic devices and testing solutions. Innovations such as molecular diagnostics, next-generation sequencing (NGS), and automation have enhanced the accuracy, speed, and efficiency of IVD manufacturing processes. These advancements assist manufacturers to meet the increasing demand for personalized medicine, point-of-care diagnostics, and faster disease detection methods. Moreover, the integration of AI-driven technologies and data analytics optimizes production workflows and quality assurance processes, enhancing precision and compliance with regulatory standards. Furthermore, numerous healthcare companies are involved in collaboration with contract manufacturers to access such novel technologies to accelerate time-to-market, reduce operational costs, and enhance product scalability. Thus, the integration of advanced technologies by service providers is estimated to drive market growth in the forthcoming years.

 Request a free sample copy or view report summary: In Vitro Diagnostics Contract Manufacturing Market Report

In Vitro Diagnostics Contract Manufacturing Market Report Highlights

• Based on product, the market includes instruments, reagents & consumables, software & services. In 2024, the reagents & consumables segment accounted for the largest revenue share of 69.41%.

• Based on service, the market is segmented into manufacturing services, assay development services, and other services. The manufacturing services segment accounted for the largest market share in 2024.

• Based on technology, the market is segmented into immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation, and others. The immunoassays segment dominated the market with the largest revenue share in 2024.

• In terms of end use, the market is segmented into medical device companies, academic & research institutions, and others. The medical device companies segment dominated the market with the largest revenue share in 2024.

• North America in vitro diagnostics contract manufacturing market dominated the global market in 2024 with the largest share of 41.83%. The in vitro diagnostics contract manufacturing market in Asia Pacific is expected to witness the fastest CAGR over the forecast period.

In Vitro Diagnostics Contract Manufacturing Market Segmentation

Grand View Research has segmented global in vitro diagnostics contract manufacturing market report based on product, service, technology, end-use, and region:

In Vitro Diagnostics Contract Manufacturing Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Reagents & Consumables

• Software & Services

In Vitro Diagnostics Contract Manufacturing Service Outlook (Revenue, USD Million, 2018 - 2030)

• Manufacturing Services

• Assay Development Services

• Other Services

In Vitro Diagnostics Contract Manufacturing Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoassays

• Clinical Chemistry

• Molecular Diagnostics

• Hematology

• Microbiology

• Coagulation

• Others

In Vitro Diagnostics Contract Manufacturing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Medical Device Companies

• Academic & Research Institutions

• Others

In Vitro Diagnostics Contract Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S.

• Canada

• Mexico

• Europe

• UK

• Germany

• France

• Italy

• Spain

• Sweden

• Denmark

• Norway

• Asia Pacific

• Japan

• China

• India

• Thailand

• South Korea

• Australia

• Latin America

• Brazil

• Argentina

• Middle East & Africa

• South Africa

• Saudi Arabia

• UAE

• Kuwait

List of Key Players of In Vitro Diagnostics Contract Manufacturing Market

• Jabil Inc.

• Sanmina Corporation

• TE Connectivity

• Celestica Inc.

• Savyon Diagnostics

• West Pharmaceutical Services, Inc.

• Thermo Fisher Scientific

• KMC Systems

• Cenogenics Corporation

• Novo Biomedical

• Cone Bioproducts

• Invetech

• AVIOQ Inc.

• Meridian Bioscience Inc.

• Nemera